Your browser doesn't support javascript.
loading
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Molife, L Rhoda; Omlin, Aurelius; Jones, Rob J; Karavasilis, Vasilios; Bloomfield, David; Lumsden, Graeme; Fong, Peter C; Olmos, David; O'Sullivan, Joe M; Pedley, Ian; Hickish, Tamas; Jenkins, Peter; Thompson, Emilda; Oommen, Nikhil; Wheatley, Duncan; Heath, Catherine; Temple, Graham; Pelling, Katy; de Bono, Johann S.
Afiliación
  • Molife LR; Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Sciences, Institute of Cancer Research/Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK.
Future Oncol ; 10(2): 219-31, 2014 Feb.
Article en En | MEDLINE | ID: mdl-24490608

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Año: 2014 Tipo del documento: Article